Proteomics International Laboratories (PIQ) Investor Presentation summary

Key highlights

• Launching four first-in-class diagnostic tests in 2025 targeting major diseases with unmet needs.

• Tests validated in large clinical studies and offer significant advantages over current standards.

• Consumer-driven strategy focuses on primary care and GP clinics, supported by a digital platform.

• Products are patented, have attractive margins, and are funded for launch strategies.

• Positioned to secure licensing agreements and strategic partnerships.

Product pipeline and commercialization

• PromarkerD predicts diabetic kidney disease onset; launches in Australia and USA in 2025.

• PromarkerEndo identifies all stages of endometriosis with high accuracy; launch in Australia in 2025, USA to follow.

• PromarkerEso diagnoses esophageal cancer; launch in Australia Q3 2025, USA pending.

• OxiDx assesses muscle damage and training recovery; launch in Australia in 2025, USA to follow.

• All products subject to relevant regulatory approvals in each country.

Market launch and growth strategy

• Focus on market awareness and rapid launch of tests for large unmet needs.

• Built platform and digital sales pathway enable tech transfer and fast product launches.

• Reimbursement pricing in the USA imminent for PromarkerD, with others to follow.

• Strategic partnerships and licensing agreements targeted to drive revenue and market adoption.

• Ongoing engagement with GP clinics, KOLs, and end users to refine sales and grow awareness.